Clinical trial
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
NCT04819100 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- December 20, 2021
- Completion date
- May 31, 2028
- Enrollment
- 152 (estimated)
- Sites
- 211
Conditions
As the registry lists them; a condition with its own page is linked.